Cognition Therapeutics, Inc. (CGTX)


+0.11 (+6.01%)
Symbol CGTX
Price $1.94
Beta 0.000
Volume Avg. 0.08M
Market Cap 56.769M
Shares () -
52 Week Range 1.07-6.269
1y Target Est -
DCF Unlevered CGTX DCF ->
DCF Levered CGTX LDCF ->
ROE -71.98% Strong Sell
ROA -61.45% Strong Sell
Operating Margin -
Debt / Equity 25.28% Neutral
P/E -1.96 Sell
P/B 1.14 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest CGTX news

Ms. Lisa Ricciardi
NASDAQ Global Market

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.